Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL

J Hepatol. 2022 Sep;77(3):695-701. doi: 10.1016/j.jhep.2022.04.009. Epub 2022 Apr 23.

Abstract

Background & aims: Detection of patients with early cirrhosis is of importance to prevent the occurrence of complications and improve prognosis. The SEAL program aimed at evaluating the usefulness of a structured screening procedure to detect cirrhosis as early as possible.

Methods: SEAL was a prospective cohort study with a control cohort from routine care data. Individuals participating in the general German health check-up after the age of 35 ("Check-up 35") at their primary care physicians were offered a questionnaire, liver function tests (aspartate and alanine aminotransferase [AST and ALT]), and follow-up. If AST/ALT levels were elevated, the AST-to-platelet ratio index (APRI) score was calculated, and patients with a score >0.5 were referred to a liver expert in secondary and/or tertiary care.

Results: A total of 11,859 participants were enrolled and available for final analysis. The control group comprised 349,570 participants of the regular Check-up 35. SEAL detected 488 individuals with elevated APRI scores (4.12%) and 45 incident cases of advanced fibrosis/cirrhosis. The standardized incidence of advanced fibrosis/cirrhosis in the screening program was slightly higher than in controls (3.83‰ vs. 3.36‰). The comparison of the chance of fibrosis/cirrhosis diagnosis in SEAL vs. in standard care was inconclusive (marginal odds ratio 1.141, one-sided 95% CI 0.801, +Inf). Of note, when patients with decompensated cirrhosis at initial diagnosis were excluded from both cohorts in a post hoc analysis, SEAL was associated with a 59% higher chance of early cirrhosis detection on average than routine care (marginal odds ratio 1.590, one-sided 95% CI 1.080, +Inf; SEAL 3.51‰, controls: 2.21‰).

Conclusions: The implementation of a structured screening program may increase the early detection rate of cirrhosis in the general population. In this context, the SEAL pathway represents a feasible and potentially cost-effective screening program.

Registration: DRKS00013460 LAY SUMMARY: Detection of patients with early liver cirrhosis is of importance to prevent the occurrence of complications and improve prognosis. This study demonstrates that the implementation of a structured screening program using easily obtainable measures of liver function may increase the early detection rate of cirrhosis in the general population. In this context, the 'SEAL' pathway represents a feasible and potentially cost-effective screening program.

Keywords: cirrhosis; liver fibrosis; non-invasive test; screening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine Transaminase
  • Aspartate Aminotransferases
  • Biomarkers
  • Fibrosis
  • Humans
  • Liver Cirrhosis* / complications
  • Liver Cirrhosis* / diagnosis
  • Liver Cirrhosis* / epidemiology
  • Platelet Count
  • Prospective Studies

Substances

  • Biomarkers
  • Aspartate Aminotransferases
  • Alanine Transaminase

Associated data

  • DRKS/DRKS00013460